Summary
BPC-157 (Body Protection Compound 157) is a synthetic pentadecapeptide of 15 amino acids, derived from a protective protein found in human gastric juice. Research has explored it across three main areas: tissue repair, gut health, and neurological function. The large majority of this evidence comes from preclinical animal studies, and human clinical data remains limited as of 2025. BPC-157 was placed into Category 2 of the FDA compounding review process in 2023 and is one of seven peptides scheduled for review by the Pharmacy Compounding Advisory Committee on July 23, 2026. In keeping with the Pepvela philosophy, understanding the research and your own baseline biomarkers is essential context before engaging with any protocol.
What Is BPC-157
BPC-157 is derived from a protein known as Body Protection Compound, which occurs naturally in small amounts in human gastric juice as part of the stomach's defense and repair mechanisms. It was first isolated in research on gastric mucosal protection, and the synthetic peptide used in studies represents a stable fragment of that larger protein.
Structurally, BPC-157 is a pentadecapeptide, meaning it is composed of 15 amino acids in a defined sequence. The version used in research is produced synthetically rather than extracted, which allows for consistent characterization in study settings.
BPC-157 attracted research interest in part because of its reported stability and because it has been studied in both oral and injectable forms across a wide range of preclinical applications. Research suggests this breadth, combined with consistent findings in animal models, is what drew attention from the recovery and longevity research communities.
What the Research Shows
Tissue Repair and Recovery Research
Much of the BPC-157 literature centers on musculoskeletal tissue. Preclinical studies indicate accelerated healing of tendon and ligament tissue in rodent models, with researchers examining outcomes such as tendon outgrowth, cell survival, and cell migration.
Animal models have also explored muscle repair, including recovery following injury, and a smaller body of work has looked at bone healing within the same preclinical context.
Research suggests several proposed mechanisms for these observations. These include upregulation of growth hormone receptor expression in injured tissue, and interaction with the nitric oxide system and VEGF, a signaling protein involved in the formation of new blood vessels and tissue repair.
An important limitation applies across this area: the findings are drawn primarily from animal studies. Whether they translate consistently to humans at the doses studied remains an open research question.
Gastrointestinal Research
BPC-157 was originally studied in a gastrointestinal context, which reflects its origin in gastric juice. Preclinical studies indicate research interest in gut lining and mucosal integrity, including how the peptide might influence the protection and repair of the intestinal lining.
Animal research has also examined BPC-157 in the context of inflammatory bowel conditions, exploring inflammatory pathways relevant to gut tissue.
Some preclinical studies indicate research into gut motility and the broader gut-brain axis, which connects to interest in dopaminergic and serotonergic signaling reported in the literature.
As with the tissue-repair work, human clinical evidence in the gastrointestinal area is limited and ongoing. The available data is largely preclinical.
Neurological and Systemic Research
Beyond tissue and gut research, animal models show research interest in neurological function. Preclinical studies indicate exploration of neuroprotective pathways and the gut-brain axis.
Systemic effects have also been studied in preclinical models, including research into stress-response pathways and how the peptide interacts with broader signaling systems.
This area is at an early stage. The available data is mostly drawn from animal research, and human evidence is limited.
Understanding the Research Limitations
Honest interpretation of BPC-157 requires understanding what the evidence does and does not establish. The large majority of published BPC-157 research has been conducted in animal models, particularly rodents. These studies are valuable for generating hypotheses, but they do not by themselves establish effects in humans.
Human clinical trials are limited in both number and scale. As of 2025, no large randomized controlled trials in humans have been published, and the existing human research consists mainly of limited case reports and small observational studies. The translation from animal to human is not yet established for most of the applications studied.
In addition, the standardization of peptide quality across research studies can vary, which makes direct comparison between studies more difficult. Researchers consider this context essential, because it distinguishes what the preclinical literature suggests from what has been demonstrated in people.
BPC-157 and the July 2026 FDA Review
BPC-157 was placed into Category 2 of the FDA's 503A compounding review process in 2023. That designation reflected concerns about immunogenicity, gaps in the available safety data, and limited human exposure data.
It is one of seven peptides scheduled for review by the Pharmacy Compounding Advisory Committee (PCAC) on July 23, 2026. The committee will examine the available evidence and discuss whether BPC-157 meets the criteria for inclusion on the 503A Bulks List, which governs the bulk substances that licensed compounding pharmacies may use.
A positive PCAC recommendation would advise the FDA Commissioner that BPC-157 could be considered for that list, which could open a regulated compounding pathway under a valid prescription. It would not mean the peptide is FDA-approved as a drug, and it would not establish it as safe or effective for any particular use. For the full picture, see FDA Peptide Advisory Panel July 2026: What Researchers Need to Know and What Is the 503A Bulks List? A Researcher's Guide.
Biomarkers Relevant to BPC-157 Research
Researchers studying BPC-157 often track biomarkers that provide context for inflammation, growth signaling, and gut health.
- CRP (C-Reactive Protein): An inflammation marker often referenced in tissue-repair and recovery research.
- IGF-1: A growth factor relevant to research on tissue repair and growth signaling pathways.
- ESR (Erythrocyte Sedimentation Rate): An additional inflammation marker sometimes tracked alongside CRP in research contexts.
- Gut permeability markers: Markers of intestinal permeability provide context for research on gut lining integrity.
Understanding your baseline biomarkers before engaging with any research protocol is the Pepvela philosophy. Read the Lab Testing Guide for more context.
Continue Your Research
BPC-157 Peptide Profile
Read the full research profile including evidence grade, stack considerations, and research cautions.
FDA Peptide Advisory Panel July 2026
Understand the July 23-24 PCAC review and what it means for BPC-157 and six other peptides.
Lab Testing Guide
Understand which biomarkers to track before engaging with any research protocol.
Peptide Safety Checker
Research peptide interaction considerations before building any protocol.
References
- Sikiric P et al. -- "Stable Gastric Pentadecapeptide BPC-157" -- Journal of Physiology Paris -- 2014
- Chang CH et al. -- "The promoting effect of pentadecapeptide BPC-157 on tendon healing involves tendon outgrowth, cell survival, and cell migration" -- Journal of Applied Physiology -- 2011
- Sikiric P et al. -- "Brain-gut Axis and Pentadecapeptide BPC-157" -- Current Neuropharmacology -- 2016
- FDA Federal Register -- Category 2 Bulk Drug Substances -- 2023
- FDA Advisory Committee Calendar -- July 23-24 2026 PCAC Meeting -- fda.gov